“The concentration of the cleaved suPAR forms in pre- and postoperative plasma samples improves the prediction of survival in colorectal cancer:
A nationwide multicenter validation and discovery study.”
Our results evaluate the prognostic biomarker potential of the soluble urokinase-type plasminogen activator receptor (suPAR) in plasma samples collected pre- and postoperatively from patients resected for colorectal cancer (CRC).
“Novel DNA methylation biomarkers show high sensitivity and specificity for blood-based detection of colorectal cancer
-a clinical biomarker discovery and validation study”
Our results show that early detection plays an essential role to reduce colorectal cancer (CRC) mortality. While current screening methods suffer from poor compliance, liquid biopsy-based strategies for cancer detection is rapidly gaining promise. Here, we describe the development of TriMeth, a minimal-invasive blood-based test for detection of early-stage colorectal cancer. The test is based on assessment of three tumour-specific DNA methylation markers in circulating cell-free DNA.
“Evaluation of algorithm development approaches: Development of biomarker panels for early detection of colorectal lesions”
Our results show that the development of algorithms can lead to a more precise method for identifying subjects with cancer.
“Genome-wide cell-free DNA fragmentation in patients with cancer”
Our results show that a newly developed assay method can detect fragments of cell-free DNA in blood samples.
In healthy subjects, the fragments are predominantly derived from leukocytes, while the fragments
in cancer patients are predominantly tumor-derived.
This method is not nearly as complex as the previous methods of DNA analysis.
Proably, analyzes of even very large quantities can, by now, be carried out, as we are now testing.
The results also show that DNA fragments can be used for the detection of subjects with cancer. Consequently, the method can, probably, improve existing methods of blood-based DNA analysis for early detection of cancer disease.
“Increased serological, cancer-associated protein biomarker levels at diagnosis of large bowel adenoma: Risk of subsequent primary malignancy?”
The results from this retrospective project show that subjects who at colonoscopy were diagnosed with pre-cancerous adenoma lesions and at the same time showed a high concentration of cancer-associated biomarkers in a blood sample have a higher risk of developing a cancerous disease during the years following colonoscopy, compared with subjects with pre-cancerous adenomas without elevated biomarker levels in the blood.
Our results show that a triage concept could improve selection to colonoscopy.
The triage test including subject age, concentration of hemoglobin in a feces test and a
combination of certain blood-based cancer associated biomarkers
may reduce the requirements for colonoscopy by around 30%.
Advantageous results for the colonoscopy-capacity, the health budgets and in particular,
the subjects, who do not need an unnecessary, unpleasant and risk-associated bowel examination.
These results are achieved through several major clinical research projects focusing on blood markers for cancer.
“Direct detection of early-stage cancers using circulating tumor DNA”
Our results show that DNA mutations in blood samples can identify 71% of those who carry an early stage colon cancer disease.
These results are generated in a collaboration between Johns Hopkins University, Baltimore, USA; MoMA, Skejby, DK—and collaborating hospitals in Denmark.
“Serological biomarkers in triage of FIT-positive subjects?”
Our results show that a combination of a person’s age, the person’s screening test for occult blood in stools (FIT) and a biomarker-test based on blood with great accuracy will identify subjects with colon cancer or adenomas.
Subjects who would bee missed in a bowel screening based on a Fit-test, alone.
A result validation:
Biological markers in blood can detect subjects at risk of developing a future cancer disease
Our basic research-hypothesis is presently confirmed as we have shown that:
elevated levels of one or more of four blood-based biological markers relate to an increased risk of developing a cancer disease within few years
The design of our current major project ─ Endoscopy III, Part 2 (2016-2022) ─ is therefore based on the research hypothesis:
A screening with a stool test for occult blood showing “no findings” could be a “false negative response” as a malignant disease intra-or,extracolonic may already be under development (cf. a potential elevated biomarker level). Upon detection of an elevated biomarker level more frequent follow-ups should be offered to diagnose possible malignancy in early stages.